Clinical trials: Cytokine Release Syndrome
SARS-CoV 2, COVID19
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome.
- Conditions
- SARS-CoV 2, COVID19, SARS (Severe Acute Respiratory Syndrome), Cytokine Release Syndrome
- Trial name
- COVIDIOL (NCT04366908)
- Testing
- BAT + Calcifediol, BAT
- Where
- Spain
- Volunteers
- 517 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytokine Release Syndrome, COVID19
Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS
This protocol will evaluate the efficacy of Therapeutic Plasma Exchange (TPE) alone or in combination with ruxolitinib in COVID positive patients with PENN grade 2, 3, 4 cytokine release syndrome (CRS).
- Trial name
- NCT04374149
- Testing
- Therapeutic Plasma Exchange, Ruxolitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Prisma Health-Upstate
Multiple Myeloma, Large B-cell Lymphoma (LBCL)
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
The purpose of this study is to evaluate emapalumab as a prophylactic therapy in preventing cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients with hematologic…
- Trial name
- NCT07567014
- Testing
- Emapalumab
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
COVID-19
Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection
To provide ruxolitinib through an expanded access program for the treatment of cytokine storm due to COVID-19 in the United States to patients who are eligible but not able to be hospitalized or who are hospitalized with a…
- Trial name
- NCT04355793
- Testing
- Ruxolitinib
- Sponsor
- Incyte Corporation
Leukemia, Acute, Myelodysplastic Syndromes
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
This research is being done to learn whether drug called itacitinib, which is a novel inflammation- and immune-lowering drug (immunosuppressant), can be given before and after non-myeloablative peripheral blood stem cell…
- Conditions
- Leukemia, Acute, Myelodysplastic Syndromes, Myelomonocytic Leukemia, Chronic, T-cell Prolymphocytic Leukemia
- Trial name
- NCT05823571
- Testing
- Itacitinib
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Efficacy and Safety of Itolizumab in COVID-19 Complications
Randomized, Parallel Group, Active Controlled Trial
- Conditions
- Acute Respiratory Distress Syndrome, Cytokine Release Syndrome, Covid19
- Trial name
- NCT04475588
- Testing
- Itolizumab IV infusion, Best supportive care (BSC)
- Where
- 4 sites in India
- Volunteers
- 32 people
- Sponsor
- Biocon Limited
Covid19, Cytokine Storm
Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
Since the end of 2019, Egypt and the whole world have been suffering from the Coronavirus Disease 2019 (COVID-19) pandemic, which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Conditions
- Covid19, Cytokine Storm, Corona Virus Infection
- Trial name
- NCT04734678
- Testing
- Tocilizumab, Infliximab
- Where
- Egypt
- Volunteers
- 153 people
- Sponsor
- Ain Shams University
Acute Lung Injury, Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to determine if APRV can reduce agitation, delirium, and…
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
- Trial name
- NCT00750204
- Testing
- APRV, Conventional MV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia
Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia
This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia…
- Trial name
- CAN-COVID (NCT04362813)
- Testing
- Canakinumab
- Where
- 39 sites in United States, France and 4 more
- Volunteers
- 454 people
- Sponsor
- Novartis Pharmaceuticals
Hematologic Cancer
TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS
Torque Teno Virus (TTV) prevalence in the general population is very high (>90%) and has not been consistently confirmed to cause any disease.
- Trial name
- TTV-CART (NCT04822974)
- Testing
- blood collection
- Volunteers
- 20 people
- Sponsor
- Institut Paoli-Calmettes
COVID-19
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Phase 2, randomized, open-label study to evaluate the safety and efficacy of maraviroc, favipiravir, and both drugs administered along with currently used therapy in hospitalized patients with pulmonary SARS-CoV-2 (Severe Acute…
- Trial name
- COMVIVIR (NCT04475991)
- Testing
- Maraviroc + Currently used therapy, Curently used therapy for COVID-19 non-critical patients, Favipiravir + Currently used therapy
- Where
- Mexico
- Volunteers
- 19 people
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe)
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
This is a multi-center, randomized, placebo controlled, interventional phase 2A trial to evaluate the safety profile and potential efficacy of multi-dosing of mesenchymal stromal cells (MSC) for patients with SARS-CoV-2…
- Conditions
- Acute Respiratory Distress Syndrome, ARDS (Moderate or Severe), COVID-19 Pneumonia
- Trial name
- NCT04466098
- Testing
- Mesenchymal stromal cells
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Acute Lymphoblastic Leukemia, CD19 Positive
CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
This is a single center,randomized ,two-cohorts, open-label ,phase 1/2 study to evaluate the efficacy and safety of T cells expressing CD19 chimeric antigen receptors treatment for relapsed/refractory CD19+ acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, CD19 Positive, Relapse, Refractory
- Trial name
- NCT03275493
- Testing
- CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia
Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
In this trial, the investigators will begin to explore the possibility that, as in mice, janus kinase inhibitor 1 (JAK1) inhibition with haploidentical-hematopoietic cell transplantation (HCT) may mitigate…
- Conditions
- Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma
- Trial name
- NCT03755414
- Testing
- Stem cell transplantation, Itacitinib, Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Washington University School of Medicine
Critical Illness, Corona Virus Infection
Anti-IL6 and Corticosteroid Monotherapy vs Combination in COVID-19
The cytokine storms mediated by over production of proinflammatory cytokines have been observed in a large population of critically ill patients infected with COVID-19.
- Conditions
- Critical Illness, Corona Virus Infection, Cytokine Release Syndrome
- Trial name
- NCT04486521
- Testing
- Interleukin 6 (IL6) Antagonist, Interleukin 6 (IL6) Antagonist and corticosteroids, corticosteroid alone
- Where
- Saudi Arabia
- Volunteers
- 860 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Cytokine Release Syndrome, CAR-T
Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)
Patients with severe CAR-T cell associated cytokine release syndrome (CRS) (defined as vasopressor dependent) will be treated with standard of care (SOC) + cytokine adsorption (6hourly for 24 hrs).
- Trial name
- CYTORELEASE (NCT04048434)
- Testing
- Cytosorb
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 34 people
- Sponsor
- Hannover Medical School
COVID-19
Safety and Efficacy of Baricitinib for COVID-19
This study plans to learn more about the effects of a medicine called baricitinib on the progression of COVID-19 (coronavirus disease of 2019), the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2…
- Trial name
- NCT04340232
- Testing
- Baricitinib
- Where
- United States
- Sponsor
- University of Colorado, Denver
SARS-CoV 2 Pneumonia
Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).
Descriptive, retrospective, observational, anonymous, study to evaluate the potential effect of incorporating calcifediol into the therapeutic protocol of patients hospitalized for COVID-19 on mortality and other outcome…
- Trial name
- COVIDIOL (NCT06279910)
- Testing
- Calcifediol
- Where
- Spain
- Volunteers
- 230 people
- Sponsor
- Complejo Hospitalario Universitario de Albacete
Cardiac Arrest, Extracorporeal Circulation
Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation
Almost all patients with refractory cardiac arrest, who are primarily stabilized under ongoing cardiopulmonary resuscitation by transcutaneous implantation of a venoarterial extracorporeal membrane oxygenation system (va-ECMO for…
- Conditions
- Cardiac Arrest, Extracorporeal Circulation, Extracorporeal Membrane Oxygenation, Cytokine Storm
- Trial name
- CYTER (NCT03685383)
- Testing
- Cytosorb removal column in eCPR, standard eCPR (va-ECMO)
- Where
- Germany
- Volunteers
- 41 people
- Sponsor
- University Hospital Freiburg
Covid19, ARDS
Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS
ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute…
- Conditions
- Covid19, ARDS, Hypoxia, Cytokine Storm
- Trial name
- NCT04657458
- Testing
- ExoFlo
- Sponsor
- Direct Biologics, LLC